Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Centre Hospitalier Universitaire De Grenoble is currently managing 2 pending office actions in the Chemistry & Materials technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units. This distribution shows that even with a small number of active matters, the company's intellectual property is being examined across different specialized departments within the patent office. This spread requires a strategy that accounts for different departmental perspectives and prevents the consolidation of prosecution under a single authority.
The busiest examiner for this portfolio is KWON, JOHN SEUNGJAI, who is responsible for 1 pending office action. Given that there are 2 pending actions and 2 distinct examiners, each examiner is handling exactly 1 action. This balance means that the company's prosecution success is not tied to a single individual, but rather depends on navigating the different standards of 2 separate art units and the individual approaches of 2 different examiners. Practitioners must prepare for distinct sets of prior art interpretations and procedural requirements for each application. The presence of 2 distinct art units suggests that the technical scope of the 2 pending office actions may vary significantly even within the same technology area, requiring specialized arguments for each matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
| BABIC, CHRISTOPHER M | 1 | 60.6% | +23.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18281642 | ANTISENSE OLIGONUCLEOTIDES FOR THEIR USE IN AN ANTI-CANCER TREATMENT | BABIC, CHRISTOPHER M | 7d |
| 18284381 | NANOSTRUCTURED BIOMIMETIC NEUROMORPHIC SYSTEM | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1712 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284381 | NANOSTRUCTURED BIOMIMETIC NEUROMORPHIC SYSTEM | KWON, JOHN SEUNGJAI | 1712 | §103 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18281642 | ANTISENSE OLIGONUCLEOTIDES FOR THEIR USE IN AN ANTI-CANCER TREATMENT | BABIC, CHRISTOPHER M | 1633 | §103 | Final Rejection | 7d | Pending | Sep 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial